Trevi Therapeutics Files 8-K: Material Agreement, Other Events
Ticker: TRVI · Form: 8-K · Filed: Jun 4, 2025 · CIK: 1563880
Sentiment: neutral
Topics: material-agreement, corporate-filing
TL;DR
TREVI filed an 8-K on 6/3 for a material agreement. Big news pending.
AI Summary
On June 3, 2025, Trevi Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement. The filing also included other events and financial statements/exhibits. The company is incorporated in Delaware and its principal executive offices are located in New Haven, Connecticut.
Why It Matters
This filing indicates significant corporate activity, including a material definitive agreement, which could impact the company's future operations and financial standing.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce significant risks and opportunities, requiring careful investor scrutiny.
Key Numbers
- 001-38886 — SEC File Number (Identifies the specific filing with the SEC)
- 45-0834299 — IRS Employer Identification No. (Tax identification number for the company)
Key Players & Entities
- Trevi Therapeutics, Inc. (company) — Registrant
- June 3, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- New Haven, Connecticut (location) — Address of Principal Executive Offices
- 203-304-2499 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement?
The filing does not specify the details of the material definitive agreement, only that one was entered into.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 3, 2025.
Where are Trevi Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 195 Church Street, 16th Floor, New Haven, Connecticut 06510.
What is Trevi Therapeutics, Inc.'s state of incorporation?
Trevi Therapeutics, Inc. is incorporated in Delaware.
What is the SEC file number for Trevi Therapeutics, Inc.?
The SEC file number is 001-38886.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 4, 2025 regarding Trevi Therapeutics, Inc. (TRVI).